{"name":"Enliven Therapeutics","slug":"enliven-therapeutics","ticker":"ELVN","exchange":"NASDAQ","domain":"enliventx.com","description":"","hq":"Boulder, CO","founded":0,"employees":"","ceo":"","sector":"Oncology / Kinase Inhibitors","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":85856000,"netIncome":-103694000,"cash":98896000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQblZLUUR2c1ZZMW1nNGtKVUlJbUZwX1NaTWVGNlRMUVd6U0NwLU9xd3Z6UHFRMk5ab0RBTEZhQzA3dEwwRVlwbWc3aGZnQktqQVZEWEtEU1huVmNPRVR1TDBlSnE1OElKV29McGNFYXNXTnhQcU51MndibmtXeVQ0ZmlMQU5fTnFCbEc3ZFFtMVRPcHJ3YTNtOXFkakJaYnN5d3hqRDRIenlfRVRhLUg5SFI4TG1mUm5yYVhncUN1RFdJUXpjWkF6S1prRWpyU0M1N0JJVWVUOUwwYTRsbTFvam9mVDdsQQ?oc=5","date":"2026-04-08","type":"deal","source":"Investing.com UK","summary":"H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com UK","headline":"H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOWHhLWEM5ekZEX3VnUEZKeGVUXzJzSnoxdmF3b0VHWlhpUG5CaXVtNmhqOW50UlZZMzNxSUdaa0tiT19CNGZnMXExZHdKQmpLWmtqWk1pM1RLak41bnI4R1ZJZFNzZUI4ZDdxMHo4RUNLbmRfVzdvWTFGTGVmbjZzRGh4cw?oc=5","date":"2026-04-07","type":"pipeline","source":"StocksToTrade","summary":"Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade","headline":"Merck’s Acquisition Sparks Surge in Enliven Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNMnlGT0tOQi1TV0t4RzlTSGZOS2VaMTlZeDgyd0JrNkV3NHJ3dDVwWGJhUTNZamNTaWlWYzloekM3aFVQbWtpWGhmai1ZUV9oV2VjYmgxSlFGeXpWT183ZGFYdVRfWDR2MC1DbXdqTDNnaUpkdHJaVk9DdmU4SnhzelA2eU9FSGxEYnc?oc=5","date":"2026-04-07","type":"pipeline","source":"timothysykes.com","summary":"Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com","headline":"Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQY2ZlQWRHVlRkVlozWndsR0xJNG5yZnRmUUpkeXYtdTk4ZWZFZG5pTE9OOEtveEJ0ZHpycTdsYllrX0RxcDBsT0NZczRwTjk4dTdydFBIVi15LW5GbWRGQXJsVmJTNTAxblpTaHZibjRxQzdrcHY4U1RqeWdoTjdrMldBV2ROYWdRdGROQTFJQU01aEJUblVTVTNyQjRqV2xkc0J6RFhvNHpKVkxYblNXTWlpMDlTZFNwSktFTVdVekRFT1ZIbVlxWk9NYU4tQkR4MVFVYkhaaHpkSUJBcmZfYVJlZEc5VWZJUGdqQ0FZOGoxbzUtcW9POERRTTUzMzRUcl9KM2V6UnVfNXpseWJz?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN)","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-14","type":"pipeline","source":"simplywall.st","summary":"Have Enliven Therapeutics Insiders Been Selling Stock? - simplywall.st","headline":"Have Enliven Therapeutics Insiders Been Selling Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOT3VkSHlNZVlVMWhsOE1vODdmcGl6TWNhd25nR3kxTDVsbFFYMmlDT25aVTVJZFQzTllMekpVSkNGcWx3cjNjeExXNWZKaWtiWnBjRjBmc1RYWDcwOWtoSlJiTWpjQmhPUmtIaXpFTW0zRGpBYkNvMEFFNVN4OW80N1piYVcxT0FoQlVJaEk4bExRZzZvMzRXUlBpRFZkckxkMUE?oc=5","date":"2026-01-09","type":"trial","source":"Endpoints News","summary":"Enliven’s Phase 1 leukemia pill data look competitive with Novartis and Terns - Endpoints News","headline":"Enliven’s Phase 1 leukemia pill data look competitive with Novartis and Terns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQZlRSb2ZwUDVUNDFueVlvbXlMTTNqMTZfY3RhTmZTa0RiYUtSZmI3VjQzYVNhcTJHU0hkNU9aT0FXenhrM1NfdHM4TTZiUnM2N2h0SmZ2YzBXWHd2WWZBMHpBRTFycERFak4zRVF2WHFDMGc0bjhPWEF6MURWLVRqckdpUVVPR1g3WnV3Z1llVHVseUU4MUlvNnFoTW85U3g5WGV0amhMN3l3NTFpTkFxZTROZUJxRVVDdUNlMERVREZ6eEtnSjZzLTlualQ?oc=5","date":"2026-01-07","type":"trial","source":"PR Newswire","summary":"Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - PR Newswire","headline":"Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNcTZHTVNLZFJRT3ZoLW5pbkxFN1dobGhKUnQ5ZUpocmIydTZhTXg5bXlYWkQwdTZlMjNnWnZKRlhZdzAtQmdKUF96U0dOY3hodjhhZjlOejBDdlFDUGRvX1BSWklDQnNkRGh2SkRhbVVnOHEzOU9JS2pVbkJpSWJjMFR3S1ljcGFVNkxyamp0aDdlc0U1WFJlZA?oc=5","date":"2025-12-12","type":"pipeline","source":"Fierce Biotech","summary":"Metabolic marketing master maneuvers to CEO—Chutes & Ladders - Fierce Biotech","headline":"Metabolic marketing master maneuvers to CEO—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPaUFEZmlOd2ZicWtTQ2xkYW5TU3ZneTVjRXFKel9jS0JVTTl1dkdLVVFuMzlzY1hsb2V0WF85cTZtYTY4VGZZQ3FHaWJTNE9GemV0VU54ZjdvTUR0OU4xSFZxQmd5Nzd4Z0pLZVlzQmVSYzVJdzNFT0VHWWtaLV9JeDVCb1ZTQWFGVXlCRzBTMFVsTFUwM0loYlFVd3ViU1ZTS0hQcGZrRlBvcUQ2bWF0ejd0SmtiUnM?oc=5","date":"2025-12-11","type":"pipeline","source":"Stock Titan","summary":"Enliven Therapeutics (Nasdaq: ELVN) taps Rick Fair as CEO, ex-Bellicum chief - Stock Titan","headline":"Enliven Therapeutics (Nasdaq: ELVN) taps Rick Fair as CEO, ex-Bellicum chief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9zUFl5N1pCSnM5bThXN2RxSVd4ZTJZSmJXbXZFUTZ6ekxBS3ZiMm42ZlVpZkw2eEN4MTB2LWs1VVJIdDlicE0wNy12X0o0ZERpZ3A2TFF5bzltME1YWHRScEtWeVZVNUp5Q1A3VG9B?oc=5","date":"2025-12-09","type":"trial","source":"Oncology Pipeline","summary":"ASH 2025 – Terns wins | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"ASH 2025 – Terns wins | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQWEhwcjFTVEI5WUFRU01KNnd3MWluTDlubzhPMzlCLVViSUF5LVFSRUpNYnFrSEZkWEhoMEJxcDJjSlVTcDlYSDlIaFhCRklBSGE2dUp5eDRCZXpMSWFFLWI1bVc4Y2FLUm9YaGRjYTdXbDVyY1NjZFdKYVk0ZzU0bkVieWFEemhtVXFROHVGQVV0UWgtV2lrdTZqbWhNNHRKZ2c?oc=5","date":"2025-12-09","type":"trial","source":"Seeking Alpha","summary":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN) - Seeking Alpha","headline":"Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again (NASDAQ:TERN)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-15","type":"pipeline","source":"simplywall.st","summary":"Companies Like Enliven Therapeutics (NASDAQ:ELVN) Are In A Position To Invest In Growth - simplywall.st","headline":"Companies Like Enliven Therapeutics (NASDAQ:ELVN) Are In A Position To Invest In Growth","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":85856000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-103694000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":98896000,"cashHistory":[],"totalAssets":476168000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}